Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Biden says baby formula shortage to ease in weeks as U.S. imports more

Published 05/13/2022, 07:58 AM
Updated 05/13/2022, 05:11 PM
© Reuters. FILE PHOTO: Empty shelves show a shortage of baby formula at a CVS store in San Antonio, Texas, U.S. May 10, 2022. REUTERS/Kaylee Greenlee Beal
ABT
-
TWTR
-

By Doina Chiacu and Susan Heavey

WASHINGTON (Reuters) -The U.S. baby formula shortage should improve dramatically in coming weeks, President Joe Biden and top officials said on Friday as the administration scrambled to reverse a shortfall that hits lower-income Americans particularly hard.

The United States is working with manufacturers to allow more importation of baby formula, Biden told reporters in the Rose Garden. "We’re going to be, in a matter of weeks or less, getting significantly more formula on shelves," he said.

Food and Drug Administration Commissioner Dr. Robert Califf said earlier on Friday the FDA will announce plans next week detailing how manufacturers and suppliers abroad will be able to import their products into the United States, as well as new options for U.S. companies.

The FDA is aiming for a streamlined process that will get more products on U.S. shelves while meeting safety, quality and labeling standards, Carliff said. The $4 billion annual U.S. baby formula market is dominated by domestic producers, with imports limited and subject to high tariffs.

"Our data indicates that in stock rates in retail stores are stabilizing but we continue to work around the clock to further increase availability," Carliff said on Twitter (NYSE:TWTR).

The Biden administration this week has come under increasing pressure to address the problem, which has roots in a February recall of some formulas by one of the nation's main manufacturers, Abbott Laboratories (NYSE:ABT).

Many U.S. parents rely on baby formula. Fewer than half of babies born in the United States were exclusively breast-fed through their first three months, according to the Centers for Disease Control and Prevention 2020 Breastfeeding Report Card.

Abbott's recall affected formulas, including certain Similac products, made at a Michigan plant after complaints about bacterial infections in infants who had consumed the products.

The shortages have been compounded by supply-chain snags and historic inflation, leaving about 40% of baby formula products out of stock nationwide, data firm Datasembly said.

President Joe Biden met on Thursday with executives from infant formula manufacturers and retailers, pressing them to do everything possible to get families access.

Retailers said their top ask is more flexibility on the types of formula they can sell, while consumers need more flexibility on the types they can buy, particularly through the 'WIC' program for low-income families, the White House said.

The nutrition program for Women, Infants and Children is a federal assistance scheme administered by U.S. states. Biden told reporters retailers like Walmart (NYSE:WMT) Inc were also looking for flexibility about the amounts of formula WIC users could buy.

Abbott said on Friday it has shipped millions of cans of infant formula powder into the United States from its Ireland facility, particularly to serve consumers who use the WIC program for low-income families.

In states where Abbott has the WIC contract, the company said it will pay rebates on competing products if Similac is not available through August.

About half of infant formula nationwide is purchased by participants using WIC benefits, the White House said, and rules set by individual states have a big effect on the availability and distribution of infant formula.

"The shortage has taken an especially dangerous toll on women and children from underserved communities," U.S. House Speaker Nancy Pelosi said.

The House of Representatives next week will bring up a bill to grant emergency authority to the WIC program to address supply-chain disruptions and recalls by relaxing non-safety-related regulations, she said in a statement on Friday.

Pelosi also said an emergency spending bill to address the infant formula shortage would advance in the House.

In other measures on Capitol Hill, the House Oversight Committee said it plans to investigate the four largest manufacturers of baby formula and seek answers on how to ramp up production and avoid any future shortage.

The committee said on Friday it sent letters seeking information to Abbott Nutrition, Mead Johnson Nutrition, Nestle USA and Perrigo.

© Reuters. FILE PHOTO: Empty shelves show a shortage of baby formula at a CVS store in San Antonio, Texas, U.S. May 10, 2022. REUTERS/Kaylee Greenlee Beal

The shortage poses a threat to families throughout the country, the letter said, "particularly those with less income who have historically experienced health in equities."

Two other House committees - House Energy and Commerce and Appropriations - planned hearings on the issue.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.